Healthcare ETFs: From Broad Exposure to Big Breakthroughs

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

ETF Trends • Jun 11, 2026

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

Zacks Investment Research • Jun 10, 2026

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

Zacks Investment Research • Jun 5, 2026

US FDA to review AI-based tool to predict drug-related liver damage

The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for ​an artificial intelligence-based drug development tool designed to ‌help predict drug-induced liver injury.

Reuters • Jun 3, 2026

PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem

VanEck Pharmaceutical ETF offers a concentrated portfolio focused exclusively on drug manufacturers. iShares Global Healthcare ETF provides broader diversification across more than 100 companies in the global medical sector.

The Motley Fool • May 27, 2026

Medical Technology Stocks: Innovation Endures As Valuations Reset

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Seeking Alpha • May 2, 2026

US FDA to monitor clinical trial data in real time in pilot program aimed at speeding approvals

The U.S. ​Food and Drug Administration launched a pilot program on Monday aimed at allowing the ‌agency to monitor clinical trial data in real time, a step the agency said could cut years from drug approval timelines and keep the U.S. competitive with China.

Reuters • Apr 28, 2026

Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution' in Public Health

Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech companies before declaring on the Invest Like the Best podcast that “2025 was probably the single most exciting year in my entire journey.

24/7 Wall Street • Apr 22, 2026

Could pressure to make money faster kill the next lifesaving pill?

When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.

Market Watch • Apr 15, 2026

Global PMI: Tracking The Sectors Hit Hardest By The Middle East War

Survey data underscored how the war in the Middle East has already had a material impact on economic growth around the world. Drilling down deeper, the data showed weaker growth trends were recorded across all major industries globally.

Seeking Alpha • Apr 12, 2026